In 2020, 9.8 percent of all incident type 2 diabetes cases and 3.1 percent of cardiovascular disease cases were attributable to sugar-sweetened beverages
WEDNESDAY, Jan. 8, 2025 (HealthDay News) — Overall, 9.8 percent of all incident type 2 diabetes (T2D) cases and 3.1 percent of incident cardiovascular disease (CVD) cases were attributable to sugar-sweetened beverages (SSBs) worldwide in 2020, according to a study published online Jan. 6 in Nature Medicine.
Laura Lara-Castor, Ph.D., from Tufts University in Boston, and colleagues incorporated data from the Global Dietary Database to estimate SSB-attributed T2D and CVD burdens across 184 countries in 1990 and 2020 globally, regionally, and nationally.
The researchers found that in 2020, 2.2 and 1.2 million new T2D cases and CVD cases, respectively, were attributable to SSBs worldwide, representing 9.8 and 3.1 percent of all incident cases, respectively. Proportional SSB-attributable burdens were higher globally among men than women, for younger than older adults, for higher- than lower-educated adults, and in urban versus rural areas. The highest SSB-attributable percentage burdens were in Latin America and the Caribbean (24.4 percent for T2D and 11.3 percent for CVD) and sub-Saharan Africa (21.5 and 10.5 percent for T2D and CVD, respectively) by world region. Sub-Saharan Africa had the largest proportional increases in SSB-attributable incident T2D and CVD from 1990 to 2020 (+8.8 and +4.4 percent, respectively).
“These findings emphasize the need for targeted interventions, accounting for social inequities and aligned with global health objectives,” the authors write. “While some policies to curb SSB intakes are currently in place in some countries, our study suggests that more work is needed.”
Several authors disclosed ties to the pharmaceutical and health technology industries.
Sugar-Sweetened Beverages May Increase Risk for Gastric Cancer
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Type 2 Diabetes Linked to Worse Menopausal Symptoms
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD
Report Highlights Substance Use in Young Adults in U.S. in 2025
Considerable Gaps Identified in LDL Cholesterol Control
Link Between Liver Fibrosis in MASLD, ASCVD Varies by Glycemic Status
Semaglutide Not Linked to Higher Neovascular Age-Related Macular Degeneration Risk